Date: 2018-05-03
Type of information: Nomination
Compound: chief business officer
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: resignation
Action mechanism:
Disease:
Details:
- • On May 3, 2018, Sangamo Therapeutics,announced that Senior Vice President and Chief Business Officer, Curt A. Herberts, III will resign from the company effective June 1, 2018 to pursue a leadership opportunity with a private biotech company. Herberts, 37, joined Sangamo in 2010 as Director of Corporate Development. In 2015, he was promoted to Vice President of Corporate Development and in December 2016 to Senior Vice President and Chief Business Officer.
Financial terms:
Latest news:
Is general: Yes
